These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12499627)

  • 1. Attenuation of biventricular pressure gradients by cibenzo-line in an 18-year-old patient with hypertrophic obstructive cardiomyopathy.
    Hiasa G; Hamada M; Shigematsu Y; Hara Y; Ohtsuka T; Ogimoto A; Saeki H; Suzuki J; Matsunaka T; Hamada H; Okura T; Hiwada K
    Circ J; 2002 Dec; 66(12):1173-5. PubMed ID: 12499627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cibenzoline on biventricular pressure gradients in a pediatric patient with hypertrophic obstructive cardiomyopathy.
    Ishikawa T; Iwashima S; Ohzeki T
    Pediatr Cardiol; 2010 Jul; 31(5):707-10. PubMed ID: 20140606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cibenzoline on regional left ventricular function in hypertrophic obstructive cardiomyopathy.
    Kondo I; Mizushige K; Nozaki S; Hirao K; Iwado Y; Ohmori K; Matsuo H
    Clin Cardiol; 2000 Sep; 23(9):689-96. PubMed ID: 11016020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of cibenzoline on left ventricular pressure gradient with sigmoid septum.
    Konishi C; Shiraishi J; Muraguchi N; Ohtsuki K; Inoue M; Tatsumi T; Azuma A; Matsubara H
    Circ J; 2004 Oct; 68(10):968-71. PubMed ID: 15459474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of cibenzoline for chest oppression and ventricular arrhythmia during effort and alcohol consumption in a patient with hypertrophic obstructive cardiomyopathy: a case report].
    Sasayama T; Horimoto M; Takeda T; Takenaka T; Inoue H; Igarashi K; Akino M; Kikuchi K
    J Cardiol; 2000 Jun; 35(6):445-50. PubMed ID: 10884982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.
    Kondo I; Mizushige K; Nozaki S; Iwado Y; Masugata H; Kohno M; Matsuo H
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):459-65. PubMed ID: 11855665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Beneficial effect of cibenzoline in a patient with hypertrophic obstructive cardiomyopathy complicated with idiopathic interstitial pneumonia].
    Saito M; Hara Y; Shigematsu Y; Ohtsuka T; Saeki H; Ogimoto A; Yokoyama A; Hamada M
    Nihon Ronen Igakkai Zasshi; 2003 Jan; 40(1):62-4. PubMed ID: 12649850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles.
    Hamada M; Aono J; Ikeda S; Watanabe K; Inaba S; Suzuki J; Ohtsuka T; Shigematsu Y
    Circ J; 2007 Oct; 71(10):1540-4. PubMed ID: 17895548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.
    Sekine T; Daimon M; Hasegawa R; Teramoto K; Kawata T; Tanaka N; Takei Y; Takazawa K; Yoshida K; Komuro I
    Heart Vessels; 2006 Nov; 21(6):350-5. PubMed ID: 17143709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.
    Hamada M; Shigematsu Y; Ikeda S; Hara Y; Okayama H; Kodama K; Ochi T; Hiwada K
    Circulation; 1997 Sep; 96(5):1520-4. PubMed ID: 9315541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrophic obstructive cardiomyopathy causing severe right and left ventricular outflow tract obstruction.
    Heper G; Celiksöz M; Atasoy S; Inceer F
    Turk Kardiyol Dern Ars; 2010 Apr; 38(3):206-10. PubMed ID: 20676000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemolytic anemia in a patient with hypertrophic obstructive cardiomyopathy.
    Kubo T; Kitaoka H; Terauchi Y; Tamura S; Okawa M; Yamasaki N; Yabe T; Doi YL
    J Cardiol; 2010 Jan; 55(1):125-9. PubMed ID: 20122559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitral regurgitation disappearance after cibenzoline treatment in a patient with hypertrophic obstructive cardiomyopathy.
    Inada K; Komukai K; Mori C; Nagasawa H; Shibata T; Mochizuki S
    Intern Med; 2004 Jan; 43(1):55-8. PubMed ID: 14964580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
    Hamada M; Shigematsu Y; Inaba S; Aono J; Ikeda S; Watanabe K; Ogimoto A; Ohtsuka T; Hara Y; Higaki J
    Circ J; 2005 Aug; 69(8):940-5. PubMed ID: 16041163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-chambered right ventricle complicated by hypertrophic obstructive cardiomyopathy diagnosed as Noonan syndrome.
    Yamamoto M; Takashio S; Nakashima N; Hanatani S; Arima Y; Sakamoto K; Yamamoto E; Kaikita K; Aoki Y; Tsujita K
    ESC Heart Fail; 2020 Apr; 7(2):721-726. PubMed ID: 32078254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic interactions between Angiotensin-converting enzyme insertion/deletion polymorphism and response to cibenzoline in patients with hypertrophic obstructive cardiomyopathy.
    Ogimoto A; Okayama H; Nagai T; Ohtsuka T; Suzuki J; Inoue K; Nishimura K; Saito M; Shigematsu Y; Hamada M; Miki T; Higaki J
    J Cardiovasc Pharmacol; 2010 May; 55(5):506-10. PubMed ID: 20179607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
    Hamada M; Ikeda S; Ohshima K; Nakamura M; Kubota N; Ogimoto A; Shigematsu Y
    J Cardiol; 2016 Mar; 67(3):279-86. PubMed ID: 26116980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic cardiomyopathy with mid-ventricular obstruction and splenic infarction associated with paroxysmal atrial fibrillation: a case report.
    Tokuyasu K; Hara Y; Matsumoto Y; Hashida H; Ikeda S; Ohtsuka T; Hiasa G; Kitami Y; Shigematsu Y; Hamada M; Hiwada K
    J Cardiol; 1999 Nov; 34(5):273-7. PubMed ID: 10579136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
    Hamada M; Shigematsu Y; Hara Y; Suzuki M; Ohtsuka T; Hiasa G; Ogimoto A; Saeki H; Suzuki J; Hiwada K
    Jpn Circ J; 2001 Jun; 65(6):531-8. PubMed ID: 11407736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.